title: CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality?
abstract: CD133, a member of the prominin family, is found in a variety of tissues with at least three variants. The function of CD133 is not well understood, but its expression is subject to changes in the microenvironment cues including bioenergetic stress. Knockout of CD133 does not affect renewal, but mammary gland branching. A point mutation of CD133 (R733C) leads to retinal disorder. CD133 is found in embryonic stem cells, normal tissue stem cells, stem cell niches, and circulating endothelial progenitors as well as cancer stem cells. Maintenance of stemness in cancer may be attributable to asymmetric cell division in association with a set of embryonic expression signatures in CD133+ tumor cells. CD133 could enrich cancer stem cells, which are associated with chemo- and radiation resistance phenotype. High CD133 is associated with poor survival in a variety of solid tumors, including lung, colon, prostate, etc. Monitoring CD133+ cells in peripheral blood, and targeting CD133 in cancer, may further predict and improve the clinical outcomes.
authors: Xiazhen
authors: X
authors: Yu
authors: Yingjie
authors: Y
authors: Lin
authors: Xie
authors: X
authors: Yan
authors: Qiang
authors: Q
authors: Tian
authors: Linheng
authors: L
authors: Li
authors: Edward H
authors: EH
authors: Lin